Dose-response effects of exercise on bone mineral density and content in postmenopausal women

Paola Gonzalo-Encabo, ¹,² Jessica McNeil, ¹ Devon J. Boyne, ¹,³ Kerry S. Courneya, ⁴ Christine M. Friedenreich ¹,³,⁵

¹ Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada
² Department of Biomedical Sciences and Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Madrid, Spain.
³ Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁴ Faculty of Kinesiology, Sport and Recreation, University of Alberta, Edmonton, Alberta, Canada
⁵ Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Short title: Exercise volume on postmenopausal bone health

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/sms.13443.

This article is protected by copyright. All rights reserved.
ABSTRACT

Exercise is one of the most widely used non-pharmacological strategies to prevent bone resorption during menopause. Given the detrimental consequences of bone demineralization, the purpose of this study was to examine the effects of prescribing different exercise volumes on bone mineral density and content in previously inactive, postmenopausal women during a 12-month intervention and one year after intervention completion. Four hundred postmenopausal women were randomized to either 150 minutes/week (MODERATE dose group) or 300 minutes/week (HIGH dose group) of aerobic exercise. Total bone mineral density (g/cm²) and bone mineral content (g) were assessed at baseline, 12-months (end of the intervention) and 24-months (follow-up) using whole body dual energy X-ray absorptiometry. At 12-months, mean bone mineral density among women in the HIGH dose group was estimated to be 0.006 g/cm² (95% CI: 0.001 – 0.010; p=0.02) higher than that of women randomized to the MODERATE dose group. At 24-months, the mean difference
between groups remained statistically significant, indicating higher mean bone mineral density among women in the HIGH dose group (0.007 g/cm²; 0.001–0.001; p=0.04). No significant differences between groups were found at any time point for bone mineral content.

In an exploratory analysis, women who completed more minutes/week of impact exercises had significantly higher mean levels of bone mineral density at 12-months compared to baseline (0.006 g/cm², 95% CI: 0.006 – 0.012; p=0.03). These findings suggest that higher volumes of exercise, especially impact exercise, lead to a smaller decline in total bone mineral density, which may remain following intervention completion.

KEY WORDS: exercise volume, osteoporosis, osteopenia, menopause.

INTRODUCTION
Menopause accelerates bone loss as a result of decreased estrogen production¹. Osteopenia and osteoporosis are conditions characterized by low bone mineral density and bone mineral content, with a heightened fracture risk²³. Affecting approximately one in three women, postmenopausal osteoporosis is a highly prevalent condition and the incidence is expected to increase in the upcoming years⁴. Osteoporosis-related fractures are associated with a high risk of mortality and morbidity in postmenopausal women⁵. Preventing the long-term loss of bone in postmenopausal women is therefore a major public health priority given its prevalence and impact on physical functionality.

Several lifestyle and pharmacologic interventions to prevent the loss of bone mineral density in women have been assessed within randomized settings⁶. Pharmacological treatments, such as the prescription of bone resorption inhibitors or bone formation stimulators, are widely used in postmenopausal osteoporosis to help maintain bone mineral...
density. However, the widespread and long-term use of these drugs is limited because of possible side effects (e.g. fever, nausea, muscle and bone pain, toxicity, heart disease, cancer).

Exercise is one of the most widely used non-pharmacological strategies to prevent bone resorption. It is generally acknowledged that regular exercise can positively influence bone metabolism. Bone is an adaptive tissue and one of the mechanisms whereby exercise can improve bone strength is by increasing muscle mass because of the mechanical load that it exerts on the skeleton. Studies have shown that the osteogenic effects of exercise are associated with activities that induce high muscle tension, such as resistance training, and high impact loading activities, such as jumping. However, findings in postmenopausal women have been inconsistent thus far, with some studies observing improvements in bone mineral density after an exercise program, while others reported no effects.

Given the detrimental consequences of bone demineralization during menopause, further research is needed to determine the optimal dose of exercise that is needed to prevent postmenopausal bone loss.

The purpose of the present study was to assess the effects of prescribing different volumes of aerobic exercise on total bone mineral density and bone mineral content changes in previously inactive postmenopausal women during a year-long intervention and one-year later. We hypothesized that women randomized to a higher dose of aerobic exercise would have a slower age-related decline in bone mineral density and content compared to women randomized to a lower dose of aerobic exercise. We also hypothesized that women who voluntarily choose to spend more time doing impact activities (e.g. running, rope skipping, walking, etc.) instead of non-impact activities (e.g. cycling, rowing, swimming, etc.) would experience the least amount of decline in bone mineral density.

This article is protected by copyright. All rights reserved.
METHODS

Study design and participants

The study design and methods for the Breast Cancer and Exercise Trial in Alberta (BETA) are described in more details elsewhere\(^1\). This study was a two-center, two-arm, 12-month randomized controlled trial conducted in Calgary and Edmonton, Alberta, Canada. A total of 400 English speaking, postmenopausal women aged 50-74 years who resided in either Calgary or Edmonton were recruited and randomized to either 150 minutes/week (MODERATE) or 300 minutes/week (HIGH) of aerobic exercise. Additional inclusion criteria included: being recreationally inactive (< 90 minutes/week of exercise or if between 90 and 120 minutes/week, having a VO\(_{2\text{max}}\) < 34 ml/kg/min as measured by a submaximal fitness test), not currently taking hormone replacement therapy, not a current smoker or excessive alcohol drinker (no more than two alcoholic drinks/day), a body mass index (BMI) of 22-40 kg/m\(^2\), not previously diagnosed with cancer, not currently participating in a weight loss program and having received physician approval for exercise participation.

Intervention

Women were randomized to either 150 minutes/week (MODERATE) or 300 minutes/week (HIGH) of aerobic exercise. All women were instructed to exercise five days/week reaching 65-75% of heart rate reserve during 30 minutes/session or 60 minutes/session. Exercise sessions were supervised on at least three days/week by certified exercise trainers at recreational facilities in Calgary and Edmonton. The exercise intervention included a 12-week ramp-up period, during which the intensity, volume and frequency of exercise were gradually increased. Women could choose to complete any type of aerobic exercise (e.g. running, walking, cycling). The adherence to the intervention was monitored by weekly exercise logs that were completed by the participants and verified by the trainers.
These logs included information on the exercise time spent in the prescribed heart rate zones and the rate of perceived exertion (Borg scale, 6-20). Subsequently, there was no intervention during the 12-month follow-up period.

**Outcomes**

*Assessment of bone mineral density and bone mineral content*

Total bone mineral density (BMD) and bone mineral content (BMC) were measured at baseline, 12- and 24-months by whole body dual energy X-ray absorptiometry (DXA). Scans were taken with a Hologic Discovery A DXA system in Calgary and a General Electric Lunar iDXA in Edmonton. The DXA scanner was calibrated every day before use. Staff members were blinded to the randomization groups. Scanning instructions and procedures were standardized for all women. The analysis of the scans was done using the same protocol in Calgary and in Edmonton.

*Covariate measures*

Baseline characteristics, which include information on medical, menstrual and reproductive history, marital status, education, employment, and history of vitamin, medication and exogenous hormone use were measured with a Baseline Health Questionnaire (BHQ). Osteoporosis medication use was derived from self-reported (yes/no) information captured with the BHQ and was used as a crude indicator of osteoporosis diagnosis. Diet during the past year was measured at baseline and at 12- and 24-months with the Canadian Diet History Questionnaire\(^1\), that was originally developed by the US National Cancer Institute.

*Statistical Analysis*

For our primary analysis, linear regression models were used to estimate the mean differences in total bone mineral density (g/cm\(^2\)) and bone mineral content (g) between
treatment arms at 12-months (end of the study) and at 24-months (follow-up) after adjusting for baseline outcome values in accordance with an intent-to-treat analysis. We re-examined these results after adjusting for baseline covariates that could influence these variables\textsuperscript{20}. These included: age (years), years since menopause (years), body fat (%), ethnicity (%), estrogen levels (pg/ml), presence of osteoporosis (yes/no), osteoporosis medication use (yes/no) and intake of calcium or vitamin D supplementation (yes/no). Assumptions of normality and homogeneity were assessed by examining quantile-quantile plots and histograms of the residuals, plots of the residuals versus the fitted values, and plots of the residuals versus the predictor variables. The assumption of linearity was examined through the inclusion of polynomial terms into the regression analysis. The presence of influential observations was assessed using Cook’s distance. Sensitivity analyses were conducted to determine if the results were robust to the removal of influential observations if present. In all analyses, we found no gross violations of the assumption of normality or homogeneity and all results were robust to the removal of the few potentially influential points that were identified using Cook’s D (results not shown). Therefore, no transformation of the data was needed for these analyses.

We examined potential effect modification for the association between years since menopause, percent body fat, osteoporosis medication use (yes/no), vitamin D or calcium supplementation use (yes/no) with bone mineral density and bone mineral content, given their dual effects on bone\textsuperscript{20}.

As an exploratory analysis, a per-protocol analysis was conducted whereby women who did not adhere to at least 90% of the exercise prescription were excluded. Including the twelve-week ramp-up period, being 90% adherent to the intervention corresponded to completing an average of 238.5 minutes and 120.7 minutes of physical activity per week over 12 months for those randomized to the HIGH and MODERATE dose arms, respectively.
In an additional exploratory analysis, we examined the association between the average amount of time spent doing impact exercises and bone mineral density. We classified activities into two categories: impact versus non-impact exercises. We classified impact exercises as those where the body touches the ground and generates a gravitational load\textsuperscript{21}. The following exercises were classified as impact exercises: running, walking, hiking, dancing, rope skipping, stair climbing, trampoline jumping, snow-shoeing, as well as playing basketball, badminton, tennis, racquetball, or participating in a group fitness class. Examples of exercises classified as being non-impact included cycling, rowing, aquafit classes, swimming, cross-country skiing, or the use of the elliptical or rope machine. We estimated the average amount of time spent doing impact exercises every week for each participant.

Analyses were conducted in STATA (version 15.1, College Station, TX: StataCorp LLC) and the data were cleaned in R Studio (version 1.1.447; Boston, MA, USA.). Statistical significance was set at $P < 0.05$.

RESULTS

Of the 400 women randomized at baseline, 379 and 330 participants had complete outcome assessments at 12- and 24-months, respectively (Figure 1). There were no differences in baseline characteristics between treatment arms except for ethnicity, calcium supplementation and multivitamin use. Women in the MODERATE group had a greater percentage of multivitamin use, calcium and vitamin D supplementation and a higher proportion of Caucasian women (Table 1). Women were, on average, 58 years of age, mainly Caucasian and overweight with a median BMI of 28 kg/m\textsuperscript{2}. Of the 379 women included in this analysis, 25 and 32 women had a diagnosis of osteoporosis in the HIGH and MODERATE dose groups, respectively, at baseline. No serious harmful events were reported during the intervention.\textsuperscript{22}
In the intention to treat analysis, mean bone mineral density among women randomized to the HIGH dose group was estimated to be 0.006 g/cm² (95% CI: 0.001 – 0.010) higher than that of women randomized to the MODERATE dose group at 12-months after adjusting for baseline outcomes (p=0.02; Table 2). At 24-months, bone mineral density for the HIGH group was estimated to be 0.007 g/cm² (0.001– 0.013) higher than the MODERATE dose group after adjusting for baseline outcomes (p=0.02; Table 2). No significant differences between groups were found for bone mineral content (BMC) at 12-months (p=0.87) or at 24-months (p=0.96) after adjusting for baseline values (Table 2).

We previously reported the changes in body fat mass (kg), lean mass (kg) and VO₂max between groups following these exercise interventions. Briefly, the mean reductions in total fat mass were significantly larger in the HIGH compared with the MODERATE dose group (least-squares mean difference, −0.96 kg, 95% CI: -1.71 – -0.22; p=0.01). Lean mass was also 0.31 kg (95% CI: -0.05 – 0.68) higher at 12 months in the HIGH compared to the MODERATE dose group, however, this difference was not statistically significant (p=0.09). Lastly, greater increases in VO₂max were noted in the HIGH vs. MODERATE groups (5.09 vs 3.09 L/kg x min; p=0.05).

Based on the per protocol analysis (n=211), the magnitude of the estimated effect for bone mineral density among women whose adherence to the prescribed exercise intervention was ≥90% was similar at 12-months compared to what was observed in the intent-to-treat analysis, and at 24-months, women among the HIGH dose group had higher bone mineral density than women in the MODERATE dose group, however, this difference was not statistically significant. Furthermore, results remained unchanged for bone mineral content, with no significant differences between groups at 12 and 24 months (results not shown). We
have previously reported adherence data during BETA, finding relatively high exercise adherence with a total program adherence of 84.5% in the MODERATE group and 75.2% in the HIGH group\textsuperscript{23}.

When testing for effect modification, we found that the use of osteoporosis medication moderated the association between exercise dose and bone mineral density, indicating that the effects of exercise dose on bone mineral density was significantly greater among women randomized to the HIGH dose group who were not using osteoporosis medication (0.008 g/cm\textsuperscript{2}, 95\%IC: 0.003 – 0.012; p=0.03). As a result of these findings, we excluded women taking osteoporosis medication from the full model (n=35). Results were not different at the end of the intervention (results not shown), but they were no longer statistically significant at the end of follow-up (-0.006 g/cm\textsuperscript{2}, 95\% CI: -0.000 – 0.012; P=0.08) when compared to our intent-to-treat results. No statistically significant interactions were found with elapsed time since menopause, body fat (%) or vitamin D and calcium supplementation for bone mineral density (Supplemental Table 1). Regarding bone mineral content, effect modification was not found for any of the potential moderators (Supplemental Table 1).

In an exploratory analysis, we examined the association between bone mineral density and the average amount of minutes/week that the women spent doing impact exercises. A total of 77,341 sessions were recorded, of which 839 (1.1\%) were missing data on the type of activity performed by the women. We observed that individuals who completed an average of >85.4 minutes/week of impact exercise over the course of a year had significantly higher mean levels of bone mineral density at 12-months (0.006 g/cm\textsuperscript{2}, 95\% CI: 0.006 – 0.012; p=0.03) compared to women who did <43 minutes/week of impact exercise (Supplemental Table 2).
DISCUSSION

To our knowledge, this trial is the first to investigate the effects of prescribing different doses of exercise on total bone mineral density and bone mineral content in postmenopausal women during a 12-month intervention and at 24-month follow-up. In this 12-month intervention, inactive postmenopausal women randomized to a HIGH dose group have statistically significant higher bone mineral density compared to the MODERATE dose group at 12 months. This difference between groups remained one year after the end of the intervention. In contrast, we did not find significant differences between groups for bone mineral content. Therefore, completing a greater volume of exercise may help prevent some of the natural age-related decreases in bone mineral density, and these benefits may remain once the intervention concludes. Lastly, completing a higher volume of impact exercises led to a smaller decrease in bone mineral density, thus supporting our second hypothesis.

The effects of exercise on bone health in postmenopausal women have been explored in several studies\(^2\), however, results remain inconsistent since not all types of exercises have shown positive effects on bone mineral density\(^25\,26\). The majority of studies have reported the effects of exercise on specific bone regions, such as lumbar spine, femoral neck or total hip, given the clinical relevance of these sites in the prevention of fracture risk\(^27\,29\). Other studies, like ours, have reported the effects of exercise on whole body bone mineral density\(^31\,34\). A comparable study is the Physical Activity for Total Health study (PATH)\(^35\) Trial, which randomized 173 postmenopausal women to a year-long aerobic exercise intervention or a stretching control group. This study reported a non-significant difference in total bone mineral density between the control and the exercise group after the intervention\(^35\). Consistent with our results, some studies did not find an increase in total bone mineral density in postmenopausal women after a moderate-intensity aerobic exercise.
intervention\textsuperscript{26,36}. In our study, we found a decrease in total bone mineral density, and one possible explanation could be related to the amount of mechanical loading and muscle tension that is needed to increase bone mass\textsuperscript{11}. The majority of women in this study chose to walk\textsuperscript{22}, which has been shown to be an insufficiently strong stimulus to help preserve bone mineral density\textsuperscript{15,24}. Impact exercise and resistance training have been shown to be very effective modes of exerting a mechanical load\textsuperscript{37,38}, hence they may lead to greater improvements in bone mineral density. Indeed, our exploratory analysis revealed that greater improvements in bone mineral density were seen in women who reported completing a greater amount of impact exercises. These results are consistent with previous studies that found benefits of impact exercises on bone health\textsuperscript{14,37}.

We noted that the effects of exercise dose on bone mineral density were significantly greater among women who were not using osteoporosis medication. Therefore, women with established osteoporosis did not show an added benefit of greater exercise volume on bone mineral density. However, these results do suggest that exercise could potentially be used as a non-pharmacological strategy to prevent postmenopausal bone loss and delay the use of osteoporosis drugs. However, these results should be interpreted with caution as there was a limited number of women taking osteoporosis medication in our intervention. Although non-significant, our results may suggest that elapsed time since menopause may modify the association between exercise and bone mineral density, where the effects of exercise dose on bone mineral density were greater in women with a longer elapsed time since menopause. Bone mineral density loss during menopause is not linear, since it decreases rapidly during the first years of menopause and then attenuates\textsuperscript{39}. It is also possible that women who had lower baseline bone mineral density may have less loss due to an inability to lose a large amount of BMD over the course of the intervention. Therefore, it is possible that our exercise
interventions were unable to prevent some of this rapid decrease in bone mineral density seen during and shortly after menopause, which corroborates previous findings reported by the PATH Trial\textsuperscript{35}.

Bone mineral content is also an indicator of fracture risk and osteoporosis\textsuperscript{3}, however, most of studies conducted in postmenopausal women have focused on reporting bone mineral density measurements\textsuperscript{24}. In the present study, we found that both BMD and BMC decreased at 12 and 24 months for both groups, whereas, there were no significant differences between the MODERATE and the HIGH group for bone mineral content. Since BMD is a ratio between BMC and bone size, variations in BMD could be attributable to variations in both of these components. Future studies should report both BMC and BMD measurements to allow for further comparisons between these measurements in various populations.

The main limitation of this study was that regional scans for bone mineral density or bone mineral content were not performed since bone measurements were not a primary outcome of BETA. Therefore, we are unable to assess the effects of these exercise interventions on the total hip or the femoral neck, which are of clinical relevance for predicting the risk of fractures. Furthermore, DXA alone cannot capture all the benefits that exercise may cause in postmenopausal bone health, such that other methods like peripheral quantitative computed tomography (pQCT) could be used to better understand the effects of exercise on bone health.

In conclusion, our results suggest that prescribing a higher dose of exercise, especially impact exercise, may attenuate some of the natural age-related declines in total bone mineral density in postmenopausal women, and that these benefits may remain once the intervention
concludes. Despite these findings, it is important to recognize that declines in bone mineral density and bone mineral content occurred in all women at 12- and at 24-months compared to baseline.

**PERSPECTIVE**

There is currently little evidence on the effects of exercise volume that may be needed to improve or prevent age-related declines in bone mineral density. To our knowledge, this is the largest study to investigate the dose-response effects of exercise on total bone mineral density. Our findings suggest that postmenopausal women could delay some of the loss in total bone mineral density by performing a greater volume of aerobic exercise, especially if this exercise has a weight-bearing component. Further studies are needed to corroborate these findings, with an emphasis on regional bone mineral density and bone mineral content measurements to understand the clinical relevance of exercise dose in bone health.

**ACKNOWLEDGMENTS**

The Calgary Study Coordinators were: Sarah MacLaughlin, Quinn Harris, Erica Roberts, and Kristen Simone. The Edmonton Study Coordinators were: Natalie Ilkiw, Ciara Kallal and Dr. Amy Speed Andrews. Calgary Exercise Trainers were: Carrie Aanderson, Alia Bharwani, Shannon Brown, Ashley Cuthbert, Sue Daniel, Julie Gowans, Marguerite Graham, Erin Korsbrek, Kathleen Kranenburg, Jessica Morrison, Jason Ng, Nicole Slot, Tania White and Kaila Wright. Edmonton Exercise Trainers were: Arne Anderson, Lisa Belanger, Jennifer Crawford, Cindy Forbes, Alyssa Hindle, Corey Kuzik, Erin McGowan, Mary Norris, Janel Park, Linda Trinh, Stephanie Voaklander and Lynne Wong. Data entry was done by: Sinead Boyle, Barbara Mercer, Carla Quesnel and Trisha Kelly. Data management, including database creation, questionnaire design, data integrity and quality control, was done by: Dr
Steven Szarka, Farit Vakhetov, and Wendy Walroth. Qinggang Wang was responsible for the randomization procedures, sample size calculations and some data verification.

The BETA Trial was funded by a research grant from the Alberta Cancer Foundation (#24404) and The BETA Ancillary grant from the Canadian Cancer Society (Research Grant No. 2011-701000). Paola Gonzalo-Encabo is supported by a Predoctoral Fellowship by the Spanish Ministry of Education, Culture and Sports and was funded by a mobility research training program by the University of Alcala. Dr Jessica McNeil is a recipient of Postdoctoral Fellowship Awards from the Canadian Institutes of Health Research and Alberta Innovates-Health Solutions. Devon J Boyne is supported by the Barrie I Strafford Doctoral Scholarship for Interdisciplinary Studies on Aging and by the Queen Elizabeth II Graduate (Doctoral) Scholarship. Dr Kerry Courneya holds a Tier I Canada Research Chair. Dr Christine Friedenreich held a Health Senior Scholar Award from Alberta Innovates-Health Solutions and the Alberta Cancer Foundation Weekend to End Women’s Cancers Breast Cancer Chair.

CONFLICT OF INTEREST

The authors of this document declare that they have no conflict of interest derived from the outcomes of this study.

AUTHOR CONTRIBUTIONS

CMF and KSC were involved in the conception and design of the study and obtained study funding. DJB conducted the data processing. PGE, JM and DJB conducted the statistical analysis and interpreted the data. PGE drafted the manuscript. All authors critically revised the manuscript for intellectual content, approved the final version of the manuscript and agreed to be accountable for all aspects of the work ensuring that questions related to the accuracy or integrity of any part of the work at appropriately investigated and resolved.

This article is protected by copyright. All rights reserved.
REFERENCES


12. Watson SL, Week BK, Weis LJ, Horan SA, Beck BR. Heavy resistance training is safe and improves bone, function, and stature in postmenopausal women with low to very low bone mass: novel early findings from the LIFTMOR trial. Osteoporos Int. 2015;26(12):2889-94.


This article is protected by copyright. All rights reserved.


with isoflavone supplementation on bone and lipids in postmenopausal women: a

29. Von Stengel S, Kemmler W, Bebenek M, Engelke K, Kalender WA. Effects of
whole-body vibration training on different devices on bone mineral density. *Med Sci

CM. The effects of hormone replacement therapy and resistance training on spine

31. Nicholson VP, McKeen MR, Slater GJ, Kerr A, Burkett BJ. Low-Load Very High-
Repetition Resistance Training Attenuates Bone Loss at the Lumbar Spine in Active

32. Chilibeck PD, Candow DG, Landeryou T, Kaviani M, Paus-Jenssen L. Effects of
Creatine and Resistance Training on Bone Health in Postmenopausal Women. *Med

33. Borer KT, Fogleman K, Gross M, La New JM, Dengel D. Walking intensity for

34. Cussler EC, Lohman TG, Going SB, et al. Weight lifted in strength training predicts

1244.

36. Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT. Effects of soy
protein isolate and moderate exercise on bone turnover and bone mineral density in


**FIGURE LEGEND**

**Figure 1.** Participant flow diagram for the BETA Trial (0-12 months) and the 12-months follow-up study (12-24 months), Alberta, Canada, 2010-2014.

**SUPPLEMENTAL DIGITAL CONTENT**

Supplemental Table 1

Supplemental Table 2

This article is protected by copyright. All rights reserved.
Table 1. Baseline covariates for the participants randomized to the HIGH and MODERATE dose groups in the Breast Cancer and Exercise Trial in Alberta (BETA), Alberta, Canada, 2010–2014 (n=379).

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>HIGH dose group (n=192)</th>
<th>MODERATE dose group (n=187)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58.5 [55.7, 62.3]</td>
<td>58 [56, 62.7]</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74.8 [67.1, 86.3]</td>
<td>76 [66.4, 87]</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.63 [1.59, 1.66]</td>
<td>1.61 [1.58, 1.66]</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>28.4 [25.3, 31.8]</td>
<td>28.75 [26, 32.9]</td>
</tr>
<tr>
<td>Age at menopause (years)</td>
<td>50 [47, 52]</td>
<td>50 [48, 52]</td>
</tr>
<tr>
<td>Years postmenopausal (years)</td>
<td>8.2 [4.7,14.0]</td>
<td>8.0 [4.5,13.4]</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian; N (%)</td>
<td>164 (85.4)</td>
<td>173 (92.5)</td>
</tr>
<tr>
<td>Other; N (%)</td>
<td>28 (14.6)</td>
<td>14 (7.5)</td>
</tr>
<tr>
<td>DXA measurements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body fat (kg)</td>
<td>29.7 [23.8, 36.8]</td>
<td>29.8 [24.3, 37.7]</td>
</tr>
<tr>
<td>Lean mass (kg)</td>
<td>43.7 [39.8, 47.9]</td>
<td>43.5 [39.5, 47.6]</td>
</tr>
<tr>
<td>Total BMC (g)</td>
<td>2142 [1957, 2411]</td>
<td>2111.00 [1890, 2412]</td>
</tr>
<tr>
<td>Total Bone Area (cm²)</td>
<td>2022 [1898, 2122]</td>
<td>1973.6 [1869, 2114]</td>
</tr>
<tr>
<td>Total BMD (g/cm²)</td>
<td>1.06 [1.01, 1.13]</td>
<td>1.08 [1.00, 1.13]</td>
</tr>
<tr>
<td>Osteoporosis; N (%)</td>
<td>25 (13.0)</td>
<td>32 (17.1)</td>
</tr>
<tr>
<td>Estrogens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrone (pg/ml)</td>
<td>36.9 [30.6, 43.7]</td>
<td>39 [30.9, 47.5]</td>
</tr>
<tr>
<td>Estradiol (pg/ml)</td>
<td>9.3 [7.2, 12.3]</td>
<td>9.7 [7.6, 12.9]</td>
</tr>
<tr>
<td>Calcium supplement; N (%)</td>
<td>82 (42.7)</td>
<td>100 (53.5)</td>
</tr>
<tr>
<td>Vitamin D Supplement; N (%)</td>
<td>121 (63.0)</td>
<td>121 (64.7)</td>
</tr>
<tr>
<td>Multivitamin Supplement; N (%)</td>
<td>66 (34.4)</td>
<td>82 (43.9)</td>
</tr>
<tr>
<td>Osteoporosis Medication; N (%)</td>
<td>15 (7.5)</td>
<td>22 (11)</td>
</tr>
</tbody>
</table>

**Note:** Values reported as median [IQR] and N (%) for continuous and categorical variables respectively.

**Abbreviations:** DXA, dual energy X-ray absorptiometry; BMC, Bone mineral content; BMD, Bone mineral density.
Table 2. Mean difference in bone mineral density (g/cm²) and bone mineral content (g) between HIGH and MODERATE dose groups at 12-months and at 24-months after adjusting for baseline values among participants in BETA, Alberta, Canada, 2010–2014.

<table>
<thead>
<tr>
<th></th>
<th>12 months</th>
<th></th>
<th>Adherence</th>
<th></th>
<th>24 months</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Baseline Mean (SD)</td>
<td>12-months</td>
<td>Mean Difference at 12-month (95% IC)</td>
<td>P-Value</td>
<td>N</td>
<td>Baseline Mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BMD (g/cm²)</strong></td>
<td></td>
<td></td>
<td>Difference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIGH</td>
<td>192</td>
<td>1.075 (0.098)</td>
<td>1.064 (0.099)</td>
<td>0.006 (0.001 – 0.010)</td>
<td>0.02</td>
<td>89</td>
<td>238.5 (0.096)</td>
</tr>
<tr>
<td>MODERATE</td>
<td>187</td>
<td>1.073 (0.098)</td>
<td>1.057 (0.101)</td>
<td></td>
<td></td>
<td>122</td>
<td>120.7 (0.099)</td>
</tr>
<tr>
<td><strong>BMC (g)</strong></td>
<td></td>
<td></td>
<td>difference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIGH</td>
<td>192</td>
<td>2198.24 (347.99)</td>
<td>2185.47 (367.27)</td>
<td>-1.26 (-17.24 – 14.72)</td>
<td>0.87</td>
<td>166</td>
<td>2199.06 (370.01)</td>
</tr>
<tr>
<td>MODERATE</td>
<td>187</td>
<td>2168.33 (387.92)</td>
<td>2158.32 (374.26)</td>
<td></td>
<td></td>
<td>164</td>
<td>2175.66 (397.36)</td>
</tr>
</tbody>
</table>
Note:

a Mean difference at 12-months between groups adjusted for baseline. The reference value is the MODERATE dose group.

b $P$-value refers to the statistical significance between arms.

c N refers to the number of women that was adherence to at least 90% of the exercise prescription.

d Mean minutes per week of exercise completed for women in the study. This average corresponds with a 90% adherence to the exercise prescription. Data are adapted from Stone et al.\textsuperscript{23}

e Mean difference at 24-months between groups adjusted for baseline. The reference value is the MODERATE dose group.

Abbreviations: $N$=number of women completing measures at baseline and 12-months and 24-months $SD$=standard deviation. CI=Confidence interval.

BMC= bone mineral content, BMD= Bone mineral density
400 Randomized

200 High dose group

5 Dropped out
   2 medical reasons
   2 non-adherent
   1 personal reasons

3 Missing DXA scans

192 Provided 12-month DXA scans

26 No 24-months follow up
   7 unable to contact
   8 refusals
   4 moved
   4 medical reasons
   3 incomplete

200 Moderate dose group

9 Dropped out
   2 medical reasons
   2 non-adherent
   5 personal reasons
   1 relocation

3 Missing DXA scans

187 Provided 12-month DXA scans

23 No 24-months follow up
   13 unable to contact
   9 refusals
   1 moved

166 Provided 24-month DXA scans

164 Provided 24-month DXA scans